ChromoTek and Proteintech recently launched Nanobodies against the SARS-CoV-2 virus. These Nanobody clones were originally developed by the group of Ulrich Rothbauer at the Natural and Medical Sciences Institute, Reutlingen, Germany. In our guest blog, Teresa Wagner and Ulrich Rothbauer discuss the development of these Nanobodies and why Nanobodies are versatile alternatives to classical antibodies in SARS-CoV-2 research.
